The Global Antibiotic Research & Development Partnership (GARDP) accelerates the development and access of treatments for drug-resistant bacterial infections. Together with public, private and non-profit partners, GARDP works to preserve the power of antibiotics for generations to come.
Antibiotic resistance can affect anyone, anywhere
Antibiotic resistance occurs when bacteria change over time and no longer respond to treatment. It is already associated with nearly 5 million deaths per year, making it one of the world’s biggest killers.
A global crisis of antibiotic resistance
Antibiotic resistance has been identified as one of the top 10 global health threats by the World Health Organization.
Antibiotic resistance is spreading all over the world as a pandemic of drug-resistant infections.
Low- and middle-income countries, and certain population groups like women and children are hit hardest.
If left unchecked, antibiotic resistance may make it too risky to carry out routine surgeries and other modern medical interventions.
GARDP is acting now to counter drug resistance and save lives
GARDP is working to deliver on its “5by2025” initiative and to expand its portfolio with new treatments for bacterial infections that pose the greatest threat to human health.
GARDP’s agreements with pharmaceutical and biotech companies have the potential to slash delays in access to antibiotics from decades to years.
We engage with all key stakeholders from the get-go to coordinate efforts in the antibiotic pipeline to develop an ecosystem of antibiotic R&D and access.
Addressing urgent threats to public health
1 in 5 deaths caused by drug-resistant infections occur in children under the age of five, and up to 3 million newborns get serious infections that lead to sepsis every year.
Serious bacterial infections & sepsis
Serious bacterial infections are among the major causes of death for people in hospitals and other healthcare settings.
Sexually transmitted infections
Gonorrhoea affects 82 million people each year, and disproportionately harms women. Resistant strains are spreading around the world.
Discovery & exploratory research
Growing drug resistance is outpacing the development of antibiotics for the most difficult-to-treat infections. Producing such antibiotics starts with the earliest stage of drug development.
Access to antibiotics
Lack of access to novel antibiotics is a global problem that acutely affects whole countries and regions as well as certain population groups like children.